ATRA Atara Biotherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ATRA

Price (delayed)

$10.16

Market cap

$91.54M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.76

Enterprise value

$133.73M

?
Relative Growth: Rel. Growth: 26
Relative Strength: Rel. Strength: 73
Relative Valuation: Rel. Valuation: 12
Relative Profitability: Rel. Profitability: 38

Atara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers ...

Highlights
Atara Biotherapeutics's quick ratio has surged by 128% QoQ
The equity has grown by 32% year-on-year and by 3.1% since the previous quarter
The EPS has plunged by 129% from the previous quarter but it has soared by 70% YoY
The net income has plunged by 129% from the previous quarter but it has increased by 39% YoY
Atara Biotherapeutics's revenue has shrunk by 88% YoY and by 81% QoQ
The gross profit has plunged by 86% YoY and by 78% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.atarabio.com
Peers: AMGN HRTX AGEN

Key stats

What are the main financial stats of ATRA

ATRA stock price

How has the Atara Biotherapeutics stock price performed over time
Intraday
5.5%
1 week
-9.77%
1 month
108.2%
1 year
21.97%
YTD
-43.84%
QTD
114.8%

Financial performance

How have Atara Biotherapeutics's revenue and profit performed over time
Revenue
$23.14M
Gross profit
$22.24M
Operating income
-$6.31M
Net income
-$9.47M
Gross margin
96.1%
Net margin
-40.9%
ATRA's operating margin has dropped by 192% since the previous quarter
The net income has plunged by 129% from the previous quarter but it has increased by 39% YoY
The operating income has plunged by 118% from the previous quarter but it has soared by 53% YoY
Atara Biotherapeutics's revenue has shrunk by 88% YoY and by 81% QoQ

Price vs fundamentals

How does ATRA's price correlate with its fundamentals

Growth

What is Atara Biotherapeutics's growth rate over time

Valuation

What is Atara Biotherapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
6.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.78
The EPS has plunged by 129% from the previous quarter but it has soared by 70% YoY
The equity has grown by 32% year-on-year and by 3.1% since the previous quarter
Atara Biotherapeutics's revenue has shrunk by 88% YoY and by 81% QoQ
ATRA's P/S is 78% below its 5-year quarterly average of 27.0

Efficiency

How efficient is Atara Biotherapeutics business performance
The ROS has plunged by 183% from the previous quarter
The company's return on assets has shrunk by 143% YoY and by 140% QoQ
Atara Biotherapeutics's return on invested capital has shrunk by 117% QoQ but it has surged by 75% YoY

Dividends

What is ATRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATRA.

Financial health

How did Atara Biotherapeutics financials performed over time
The total assets is 65% less than the total liabilities
Atara Biotherapeutics's current ratio has soared by 163% from the previous quarter
Atara Biotherapeutics's quick ratio has surged by 128% QoQ
The equity has grown by 32% year-on-year and by 3.1% since the previous quarter
The debt has decreased by 24% YoY and by 2.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.